These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 37607321)
1. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. Baek SY; Noh WC; Ahn SH; Kim HA; Ryu JM; Kim SI; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Jeong J; Park E; Kim SY; Lee MH; Kim LS; Lim W; Kim S; Kim HJ J Clin Oncol; 2023 Nov; 41(31):4864-4871. PubMed ID: 37607321 [TBL] [Abstract][Full Text] [Related]
2. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. Kim HA; Lee JW; Nam SJ; Park BW; Im SA; Lee ES; Jung YS; Yoon JH; Kang SS; Lee SJ; Park KH; Jeong J; Cho SH; Kim SY; Kim LS; Moon BI; Lee MH; Kim TH; Park C; Jung SH; Gwak G; Kim J; Kang SH; Jin YW; Kim HJ; Han SH; Han W; Hur MH; Noh WC; J Clin Oncol; 2020 Feb; 38(5):434-443. PubMed ID: 31518174 [TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Bui KT; Willson ML; Goel S; Beith J; Goodwin A Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074 [TBL] [Abstract][Full Text] [Related]
4. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study. Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057 [TBL] [Abstract][Full Text] [Related]
5. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523 [TBL] [Abstract][Full Text] [Related]
6. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study. Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022 [TBL] [Abstract][Full Text] [Related]
7. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302 [TBL] [Abstract][Full Text] [Related]
8. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report. Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM; J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334 [No Abstract] [Full Text] [Related]
10. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Francis PA Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Pagani O; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Goetz MP; Ciruelos EM; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Chini C; Puglisi F; Spazzapan S; Ruhstaller T; Winer EP; Ruepp B; Loi S; Coates AS; Gelber RD; Goldhirsch A; Regan MM; Francis PA; J Clin Oncol; 2023 Mar; 41(7):1376-1382. PubMed ID: 36521078 [No Abstract] [Full Text] [Related]
13. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816 [TBL] [Abstract][Full Text] [Related]
14. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ; J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis. Jiang M; Chen W; Hu Y; Chen C; Li H Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958 [TBL] [Abstract][Full Text] [Related]
16. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM; J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China. Zhong X; Chen P; He P; Wu Y; Suo J; Zhu K; Yan X; Tian T; Yang Q; Luo T Clin Breast Cancer; 2024 Feb; 24(2):e41-e50. PubMed ID: 37865566 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer. Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis. Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567 [TBL] [Abstract][Full Text] [Related]